Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy

Frontiers in Oncology

Maria Angelica Breve²  Luca D’ Andrea²  Daniela Montorio²  Giovanni Cennamo²  Gilda Cennamo³  Raffaele Liuzzi⁴  Antonio Farella⁵  Sabino De Placido⁶  Elide Matano⁶  Mario Giuliano⁶ 

[1] Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy;Department of Neurosciences, Reproductive Sciences and Dentistry, University of Naples “Federico II”, Naples, Italy;Eye Clinic, Public Health Department, University of Naples “Federico II”, Naples, Italy;Institute of Biostructure and Bioimaging, National Research Council (CNR),Naples, Italy;Radiotherapy Unit, University of Naples “Federico II”, Naples, Italy;Rare Cancer Coordinating Center – Campania Region, Naples, Italy;

关键词: ruthenium-106 brachytherapy;    uveal melanoma;    survival rate;    local recurrence;    metastasis;    complications;   

DOI  :  10.3389/fonc.2021.754108

来源: DOAJ

【 摘 要 】

Uveal melanoma is the most common primary intraocular malignancy. The aim of this retrospective study was to report the results after ruthenium-106 (Ru-106) plaque brachytherapy for uveal melanoma in terms of tumor control, visual acuity, radiation-related complications, tumor recurrence, metastases, and patients’ survival rate during 4 years’ follow-up. A total of 355 eyes from 355 patients have been treated with Ru-106 plaque brachytherapy for uveal melanoma between February 2011 and March 2020. Five patients were lost to follow-up, and then 350 eyes of 350 patients (mean age 58 ± 11 years) were enrolled in this retrospective study. All patients underwent a complete ophthalmic examination including echography and spectral domain–optical coherence tomography. The mean follow-up was 4 years (3 months to 9 years). After treatment, the mean tumor thickness was reduced to 1.75 ± 0.21 mm. Radiation complications were found in 63% of patients: 38% showed radiation maculopathy, 11% had optic neuropathy, and 14% developed cataracts. Cancer-free survival was 99%, 97%, and 85%, respectively, at 5, 7, and 9 years. Ru-106 plaque brachytherapy represents a reliable treatment of uveal melanoma. This technique is valid and safe with a low rate of ocular complications during a long-term follow-up.

【 授权许可】

Unknown